Arjun V. Balar, MD
Associate Professor of Medicine
Director, Genitourinary Medical Oncology Program
Laura and Isaac Perlmutter Cancer Center
NYU Langone Health
New York, NY
This online activity will be a faculty-led didactic and case-based lecture focusing on treatment and management of patients with renal cell carcinoma.
This educational activity is intended for US-based community oncologists and the multidisciplinary care team involved in the management of patients with RCC.
After completing the CME activity, learners should be better able to:
- Interpret evidence from clinical trials assessing first-line combination IO/TKI therapies for the treatment of patients with advanced and/or mRCC
- Differentiate patients with advanced and/or mRCC in your care that could benefit from first-line IO/TKI combination therapies
- Formulate management strategies that account for irAEs and trAEs associated with first-line combination IO/TKI therapies for the treatment of patients with advanced and/or mRCC
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.
NURSING CREDIT INFORMATION
CNE Accreditation Statement: Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Purpose: This program would be beneficial for nurses involved in the care of patients with renal cell carcinoma.
Credits: 1.0 ANCC Contact Hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Arjun V. Balar, MD reports the following disclosures:
|Consultant/Advisor||Genentech, Incyte, Janssen, Merck, Pfizer, AstraZeneca/ Medimmune, Nektar, Seattle Genetics, and Immunomedics|
|Contracted Research (to his institution)||Genentech, Nektar, Merck, AstraZeneca/Medimmune, Seattle Genetics, and Immunomedics|
|Speaking Engagements||Genentech, Merck, and AstraZeneca/Medimmune|
|Steering Committees/Scientific Advisory Committees||Merck and Nektar|
|Equity and serves as a Scientific Advisory Board Member||EpiVax Oncology|
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff, Planners, and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Chris Drury, MA, MS, MBA, Medical Director for Med Learning Group, has nothing to disclose.
Felecia Beachum, Program Manager of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Brianna Hanson, MPH, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form to Med Learning Group.
You will receive your certificate as a downloadable file.
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected].
RELEASE DATE: June 30, 2021
EXPIRATION DATE: June 30, 2022
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected].
Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.